SEC Form 4 · accession 0001209191-18-004356
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harold E Selick
Director
Period of report
Jan 16, 2018
Accepted (ET)
Jan 18, 2018 · 6:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $157.20 | Jan 16, 2018 | D | 197 | D | — | May 13, 2020 | Common Stock | 197 | 0 | D |
| Stock Option (Right to Buy)F3 | $157.20 | Jan 16, 2018 | A | 197 | A | Jan 16, 2018 | Jul 11, 2020 | Common Stock | 197 | 197 | D |
| Stock Option (Right to Buy)F1,F2 | $66.00 | Jan 16, 2018 | D | 550 | D | — | Oct 22, 2025 | Common Stock | 550 | 0 | D |
| Stock Option (Right to Buy)F3 | $66.00 | Jan 16, 2018 | A | 550 | A | Jan 16, 2018 | Jul 11, 2020 | Common Stock | 550 | 550 | D |
| Stock Option (Right to Buy)F1,F2 | $66.00 | Jan 16, 2018 | D | 450 | D | — | Oct 22, 2025 | Common Stock | 450 | 0 | D |
| Stock Option (Right to Buy)F3 | $66.00 | Jan 16, 2018 | A | 450 | A | Jan 16, 2018 | Jul 11, 2020 | Common Stock | 450 | 450 | D |
| Stock Option (Right to Buy)F1,F2 | $28.20 | Jan 16, 2018 | D | 500 | D | — | Jun 9, 2026 | Common Stock | 500 | 0 | D |
| Stock Option (Right to Buy)F3 | $28.20 | Jan 16, 2018 | A | 500 | A | Jan 16, 2018 | Jul 11, 2020 | Common Stock | 500 | 500 | D |
| Stock Option (Right to Buy)F2 | $4.40 | Jan 16, 2018 | D | 10,000 | D | Jun 15, 2018 | Jul 13, 2027 | Common Stock | 10,000 | 0 | D |
| Stock Option (Right to Buy)F3 | $4.40 | Jan 16, 2018 | A | 10,000 | A | Jan 16, 2018 | Jul 11, 2020 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Reflects a fifteen-for-one reverse stock split on February 10, 2017.
- F2The option is fully vested and exercisable.
- F3The reported transactions involved an amendment to the post-termination exercise period of outstanding options, resulting in the deemed cancellation of the vested options and the grant of replacement fully vested options.